Claims

1. A pharmaceutical composition comprising:

{1S-[1α, 2α, 3β (1S*,2R*),5β]}-3-(7-{[2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol;

one or more fillers selected from mannitol, sorbitol, dibasic calcium phosphate dihydrate, dibasic calcium phosphate anhydrate and tribasic calcium phosphate or a mixture thereof;

one or more binders selected from alginic acid, carboxymethylcellulose sodium, copovidone and methylcellulose or a mixture thereof;

one or more disintegrants selected from croscarmellose sodium and crospovidone or a mixture thereof; and one or more lubricants.

2. A pharmaceutical composition as defined in claim 1 wherein the filler is a mixture of mannitol and dibasic calcium phosphate dihydrate.

3. A pharmaceutical composition as defined in claim 1 or 2 wherein the lubricant is selected from magnesium stearate and sodium stearyl fumarate.

4. A pharmaceutical composition as defined in claim 2 or 3 wherein {1S-[1α, 2α, 3β (1S*,2R*),5β]}-3-(7-{[2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol is present in an amount of 20 to 45% by weight.

5. A pharmaceutical composition as defined in any one of claims 2 to 4 wherein the filler is present in an amount of 20 to 70% by weight.

6. A pharmaceutical composition as defined in any one of claims 2 to 5 wherein the binder is present in an amount of 3 to 6% by weight.

7. A pharmaceutical composition as defined in any one of claims 2 to 6 wherein the disintegrant is present in an amount of 2 to 6% by weight.

8. A pharmaceutical composition as defined in any one of claims 2 to 7 wherein the lubricant is present in an amount of 0.5 to 1% by weight.

9. A pharmaceutical composition as defined in any one of claims 2 to 8 wherein {1S-[1α, 2α, 3β (1S*,2R*),5β]}-3-(7-{[2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol is substantially present in the form of Polymorph II.

10. A pharmaceutical composition as defined in any one of claims 2 to 8 wherein {1S-[1α, 2α, 3β (1S*,2R*),5β]}-3-(7-{[2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol is substantially present in the form of Polymorph III.

11. A pharmaceutical composition as defined in any one of claims 1 to 10, which has been prepared by a wet granulation process.

12. A pharmaceutical composition as defined in any one of claims 1 to 11, which has been prepared by a high shear wet granulation process.